Enanta Pharmaceuticals | ENTA - Operating Expenses


Enanta Pharmaceuticals reported $126.59M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026